Long-term safety study of Duchenne muscular dystrophy treatment
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This long-term study is for people with Duchenne muscular dystrophy who have already completed an earlier trial of the study medicine. It aims to check the safety and effectiveness of the treatment over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed one of the earlier studies (ENTR-601-44-201 or ENTR-601-45-201).
- You must be able to give consent (if you are an adult) or agreement (if you are a child).
- If you are sexually active with a female partner who could become pregnant, you must agree to use condoms.
- You cannot have any new health issues from the earlier study that would make this study unsafe for you.
- You must be willing and able to follow all study rules and appointments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ENTR-601-45 for people with Duchenne muscular dystrophy that can be treated with 'exon 45 skipping.' The goal is to see if it's safe and helps improve muscle function. It's for males between 4 and 20 who can still walk and have enough arm strength.
This trial tests a new medicine called ENTR-601-44 for people with Duchenne muscular dystrophy whose genetic mutation can be treated by skipping a part of the gene called exon 44. The goal is to see if it is safe and helps with muscle function.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
This is a long-term follow-up study for people with Duchenne muscular dystrophy who already took part in a previous SAT-3247 trial. It checks how safe and effective the treatment stays over a longer time.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This study tracks development and health in young boys with Duchenne muscular dystrophy during the first three years of life. It aims to better understand early signs and how the condition progresses, which may help improve care and future treatments.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.